Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shree PacetronixBOM:527005 +0.11%83 Peter Lynch Fair Value is ₹216.00 as of Aug. 19, 2026, which is 100% below its 10-year median of 0.65. GuruFocus rates BOM:527005 with a GF Score™ of 83/100 and a GF Value™ of ₹163.50 (Modestly Undervalued). Among 150 Medical Devices & Instruments companies, Shree Pacetronix ranks better than 86% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Shree Pacetronix's PEG is 1. Shree Pacetronix's 5-Year TTM EBITDA Growth Rate is 25.
Shree Pacetronix's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was ₹8.64. Therefore, the Peter Lynch Fair Value for today is ₹216.00.
As of today (2026-08-19), Shree Pacetronix's share price is ₹132.20. Shree Pacetronix's Peter Lynch fair value is ₹216.00. Therefore, Shree Pacetronix's Price to Peter Lynch Fair Value Ratio for today is 0.61.
The historical rank and industry rank for Shree Pacetronix's Peter Lynch Fair Value or its related term are showing as below:
BOM:527005'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.42 Med: 0.65 Max: 15.03
Current: 0.61
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Shree Pacetronix was 15.03. The lowest was 0.42. And the median was 0.65.
BOM:527005's Price-to-Peter-Lynch-Fair-Value is ranked better than 86% of 150
companies
in the Medical Devices & Instruments industry
Industry Median: 1.46
vs BOM:527005: 0.61
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Shree Pacetronix (BOM:527005) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.
Shree Pacetronix's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
132.20
/
216.00
=
0.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shree Pacetronix Peter Lynch Fair Value Related Terms
Shree Pacetronix Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Shree Pacetronix's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:527005 vs ISRG, BDX, MDLN: Peter Lynch Fair Value Comparison
For the Medical Instruments & Supplies subindustry, Shree Pacetronix's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shree Pacetronix Price-to-Peter-Lynch-Fair-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Shree Pacetronix's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Shree Pacetronix's Price-to-Peter-Lynch-Fair-Value falls into.
Shree Pacetronix's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8.64.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of ₹216.00 mean?
Shree Pacetronix (BOM:527005) has a Peter Lynch Fair Value of ₹216.00 as of Aug. 19, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Shree Pacetronix and its competitors. This is 33131% above median its historical median of 0.65. Over the past decade, Shree Pacetronix's Peter Lynch Fair Value has ranged from 0.42 to 15.03. According to the industry distribution chart, Shree Pacetronix ranks #21 out of 150 companies in the Medical Devices & Instruments industry, placing it in the top 14%.
Is Shree Pacetronix's Peter Lynch Fair Value too high?
Shree Pacetronix's current Peter Lynch Fair Value of ₹216.00 is 33131% above median its 10-year median of 0.65. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 15.03. Based on the distribution chart, Shree Pacetronix ranks #21 out of 150 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Shree Pacetronix has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shree Pacetronix's Peter Lynch Fair Value compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Shree Pacetronix ranks #21 out of 150 companies for Peter Lynch Fair Value. This places Shree Pacetronix in the top 14% of its industry — outperforming the majority of peers. The industry median Peter Lynch Fair Value is 1.46. Historically, Shree Pacetronix's own Peter Lynch Fair Value has ranged from 0.42 to 15.03 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Medical Devices & Instruments company?
The median Peter Lynch Fair Value among Medical Devices & Instruments companies is 1.46, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Shree Pacetronix and its competitors. For the Medical Devices & Instruments industry, the median Peter Lynch Fair Value is 1.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shree Pacetronix's current Peter Lynch Fair Value is ₹216.00, which is 33131% above median its own 10-year median of 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shree Pacetronix stock overvalued right now?
Based on GuruFocus' analysis, Shree Pacetronix (BOM:527005) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹163.50, compared to a current price of ₹132.20 — trading 19.1% below its estimated fair value. The current Peter Lynch Fair Value is ₹216.00, which is 33131% above median its 10-year median of 0.65. Shree Pacetronix's overall GF Score™ is 83/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Shree Pacetronix (BOM:527005), the current Peter Lynch Fair Value is ₹216.00 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shree Pacetronix (BOM:527005) Overvalued in 2026?
Based on GuruFocus' analysis, Shree Pacetronix stock appears to be undervalued.
The current stock price of ₹132.20 is trading 19.1% below its estimated GF Value™ of ₹163.50.
GuruFocus considers Shree Pacetronix to be Modestly Undervalued.
Key valuation signals for BOM:527005:
Peter Lynch Fair Value: ₹216.00 (33131% above median its 10-year median of 0.65)
GF Value™: ₹163.50 vs. price of ₹132.20 (19.1% below fair value)
No single metric tells the full story. See the BOM:527005 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shree Pacetronix Ltd is engaged in the manufacturing of medical and surgical equipment and orthopedic appliances. It is in the business of manufacturing and selling Implantable Cardiac Pacemakers. Pacemakers are anti-bradycardia implantable devices intended for permanent ventricular or atrial pacing applications. The Company is engaged in only one segment i.e. Life Saving Devices. It sells its life-saving devices in India and internationally, of which the majority of revenue is generated from the sales made in India.
83GF Score
Get the complete analysis for BOM:527005
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:527005 has been successfully added to your 
